School And Public Health Nurses Association




In this section you can catch up on all the latest news from SAPHNA and around the profession.

Who to raise your issues to re Auto Adrenaline Injector Shortage-latest update from PHE

Sharon White - Saturday, October 26, 2019 -


Despite the support and advice below, we know from our meetings and communications that many of you;

parents, professionals, pharmacists, public, are still struggling with obtaining x2in date  AAI's.

We have been advised that in order to further represent this, then you need to raise directly.

The following are the named persons to direct these to in addition to your local MP.

We hope this helps as, in our opinion,the current situation is wholly unacceptable, dangerous and of great concern!



Department of Health and Social Care:

Pharmacist Medicine Supply team

Medicines and Pharmacy Directorate

Department of Health and Social Care

South Wing, Floor 3, 39 Victoria St,

London SW1H 0EU

Lead Commissioner Community long term conditions DHSC




Public Health England



Deputy Chief Nurse - Children, young people & Families &

DeputyHead of World Health Organisation Collaborating Centre for Public Health Nursing and Midwifery

Chief Nurse, Maternity and Early Years Directorate

Public Health England

Wellington House

London SE1 8UG

Michele Lawrence

Safeguarding lead nurse

Public Health England


Wellington House

London SE1 8UG


NHS England

Head of Safeguarding


NHS England/NHSi


Head of Children , Young People and Transition at NHS Improvement and NHS England



Update from PHE Oct 2019


The Department of Health and Social Care have confirmed that all strengths of Jext, EpiPen and Emerade

adrenaline auto-injectors (AAIs) are currently available. Any parents with children who need an AAI should therefore

be able to obtain through their pharmacy.


As you may be aware, on 3rd October 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) issued

a drug alert relating to all strength Emerade devices. This was in response to Bausch & Lomb reporting instances of

Emerade devices that failed to activate. Emerade devices have not been recalled and may continue to be prescribed,

dispensed and used by patients although the alert reemphasises the importance of carrying two auto-injectors at all times


To ease the recent supply issues, the MHRA has approved the extension of expiry dates for specific batches of

EpiPen 300 micrograms and Jext 150 micrograms and 300 micrograms by four months beyond the labelled expiry date.

The expiry date means that the AAI should not be used after the end of the month listed. This applies to the original

expiry date or the extended expiry date. The company websites list the specific batches that can have their original expiry

date extended:

Mylan UK:

ALK-Abello Ltd:


DHSC continues to closely monitor the supply position for all AAIs to ensure that patients can continue to receive the

treatment that they need and current supplies are sufficient to meet normal UK requirements.


We have not received any public or other queries on this issue so hopefully the advice is quite wide spread and

parents are reassured


I hope this is helpful and please do come back with any further queries



Wendy Nicholson MBE

Deputy Chief Nurse Children, Young People & Families/Deputy Head of World Health Organization Collaborating Centre for Public Health Nursing and Midwifery

Chief Nurse, Maternity and Early years Directorate

Public Health England

Recent Posts





Pinfold House (10)

Pinfold Rise


LS25 3EN






© School And Public Health Nurses Association 2019. All rights reserved. Registered charity No: 1162042.

SAPHNA and the SAPHNA logo are trademarks of the School And Public Health Nurses Association.